<DOC>
	<DOCNO>NCT02931136</DOCNO>
	<brief_summary>The purpose study base Flutemetamol-PET senile plaque image investigate peripheral blood biochemical brain MRI image biomarkers research completely independent intellectual property right neuropsychological test tool MCI due AD . At time , investigator study efficacy safety early treatment MCI due AD Huperzine A 52 week .</brief_summary>
	<brief_title>Early Diagnosis Early Treatment Alzheimer 's Disease Based Senile Plaque Imaging</brief_title>
	<detailed_description>This randmized , double-blind , placebo-controll study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Plaque , Amyloid</mesh_term>
	<mesh_term>Huperzine A</mesh_term>
	<criteria>memory complaint , preferably corroborate spouse relative . objective memory impairment . normal general cognitive function . intact activity daily live . absence dementia . positive brain senile plaque . two lacuna ischemia ( diameter &lt; 1 cm ) reveal MRI fluidattenuated inversion recovery ( FLAIR ) sequence . type dementia except AD</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>